Balanced Outlook Amidst Strategic Shifts: Pfizer's Hold Rating Explained
Pfizer's Acoramidis Shows Promising Survival Trends: A Buy Rating Endorsement
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Wells Fargo Remains a Hold on Pfizer (PFE)
DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
Pfizer Analyst Ratings
Pfizer Exceeds Q1 Expectations With Strong Earnings and Raises 2024 Guidance: A Buy Rating by Evan Seigerman
Leerink Adjusts Price Target on Pfizer to $29 From $27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Alkermes (ALKS)
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating
Pfizer (PFE) Receives a Hold From Barclays
Buy Rating Affirmed for Pfizer Amid Strong Q1 Performance and Strategic Cost Savings
Jefferies Remains a Buy on Pfizer (PFE)
Analysts Offer Insights on Healthcare Companies: SurModics (SRDX) and Pfizer (PFE)
UBS Reaffirms Their Hold Rating on Pfizer (PFE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)
Pfizer Analyst Ratings
Pfizer Analyst Ratings
No Data